Craig-Hallum reiterates a Buy rating on Rezolute with a $13 price target after FDA completely removed the partial clinical holds on RZ358. Now that this “major overhang is lifted,” investors can look forward to a topline readout of the global Phase III congenital hyperinsulinism sunRIZE study in the second half of 2025, the analyst tells investors in a research note. The firm believes the RZ358 program is well positioned “and now otherwise unencumbered.” Hallum believes the worldwide market for congenital hyperinsulinism represents $1B in potential peak sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute’s RZ358 Advances with FDA Clearance for Study
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
- FDA lifts partial clinical holds on Rezolute’s RZ358
- Rezolute to Participate in Upcoming Investor Conferences
- Rezolute initiated with a Buy at Guggenheim on potential in CHI
Questions or Comments about the article? Write to editor@tipranks.com